companiesandmarkets.com

Return to Report | Print

Premium Company Profile - Human Genome Sciences

http://www.companiesandmarkets.com/Summary-Company-Profile/premium-company-profile-human-genome-sciences-41250.asp

Report Summary

Introduction

HGS has a broad portfolio of product candidates which are under clinical development for use in large therapeutic categories including immunology, infectious disease and oncology.

The company has three products advancing into late-stage clinical development: Albuferon for chronic hepatitis C, Lymphostat-B for systemic lupus erythematosus, and Abthraxtm for anthrax disease.

The company’s biggest contributor to sales growth out to 2010 continues to be revenues from R&D contracts. Revenues from R&D contracts are expected to increase at a CAGR of 61%, from $26 million in 2006 to $172 million in 2010. Revenue from product sales includes, Albuferon and LymphoStat- B which is expected to be launched in 2010.

Scope

  • Access all the important information and analysis on a company in a single report
  • Understand company’s strengths, weaknesses, opportunities and threats along with business strategy and value chain
  • Gain access to company’s adjusted five year financial data along with key ratios and market capitalization


    • Highlights



    Reasons to Purchase

    Table of Contents

    TABLE OF CONTENTS
    Overview 1
    Catalyst 1
    Summary 1
    Company structure 6
    Company Overview and Key Facts 6
    Business Description 7
    History 9
    Company Financials 11
    Stock Market Performance 11
    P&L 12
    Balance Sheet 14
    Cash Flow 14
    Business Segment Performance 15
    Products & Services 16
    Pipeline Products 16
    AC Forecast Sales 19
    Competitors and Strategic Business Relationships 21
    Top Competitors 21
    Key Suppliers 21
    Key Clients 21
    Shareholding Structure 23
    Strategy 24
    Company View 24
    Strategy 27
    SWOT Analysis 29
    Overview 29
    Strengths 30
    Weaknesses 31
    Opportunities 32
    Threats 33
    Value Chain Analysis 34
    Overview 34
    Scorecard 36
    Overview 36
    Scorecard Analysis 37
    Key Employees 38
    Key Employee Biographies 39
    Financial and Operational Overview 50
    Financial and Operational Overview 50
    Appendix 53
    Ask the analyst 53
    Datamonitor consulting 53
    Disclaimer 53

    TABLE OF FIGURES
    Figure 1: HGS - Operating Revenue/Cost Analysis, 2002-2006 ($ Mn) 13
    Figure 2: HGS - Key Strategic Revenues, 2006-2010 ($ Mn) 20

    TABLE OF TABLES
    Table 1: HGS - Key Facts 6
    Table 2: HGS - Year-End Share Price and Market Capitalization, 2002-2006 ($) 11
    Table 3: HGS - Key Events Impacting Share Price Performance 11
    Table 4: HGS - Operating Revenue/Cost Analysis, 2002-2006 ($ Mn) 12
    Table 5: HGS - Operating Cost Ratio Analysis, 2002-2006 (% of total revenues) 14
    Table 6: HGS - Balance Sheet, 2002-2006 ($ Mn) 14
    Table 7: HGS - Cash Flow, 2002-2006 ($ Mn) 14
    Table 8: HGS - Revenue Breakdown, 2002-2006 ($ Mn) 15
    Table 9: HGS - In-house Pipeline Products 16
    Table 10: HGS - Collaboration Pipeline Products 17
    Table 11: HGS - Forecast Sales, 2006-2010 ($ Mn) 19
    Table 12: HGS - Top Competitors 21
    Table 13: HGS – Key Clients 22
    Table 14: HGS - Key Shareholders 23
    Table 15: HGS - SWOT Analysis Summary 29
    Table 16: HGS – Value Chain Analysis 34
    Table 17: HGS - Scorecard 36
    Table 18: HGS - Key Employees 38
    Table 19: HGS – Financial and Operational Overview 51